At Frontage, we offer extensive drug metabolism and pharmacokinetic capabilities for new chemical entities and compounds in development. We provide rapid turnaround of high-quality key DMPK data sets to support critical decisions in advancing potential therapeutic agents for further development. Our highly trained scientific staff applies state-of-the-art techniques and best-in-class approaches to provide broad and in-depth expertise/advice to clients on appropriate study designs, execution of studies, and interpretation of the data. DMPK studies can provide critical data during discovery and development of pharmaceutical and agrochemical products. Frontage’s DMPK services, performed in accredited facilities, can help support lead drug candidate or chemical selection, or help you meet specific regulatory requirements.

Frontage’s newest facility in Hayward, CA started operations in 2022. With over 19,000 in. square footage, it supports bioanalytical and biologics projects. The Biologics Services Department provides exploratory and GLP-compliant Ligand Binding Assay (LBA) services to biotech and pharmaceutical industries, supporting pharmacokinetics (PK), immunogenicity (ADA), and biomarker analysis for protein therapeutics. The Bioanalytical Services Department provides R&D and GLP-compliant, quantitative mass spectrometry services to biotech and pharmaceutical industries, supporting all preclinical and clinical PK / TK / DDI / BA / BE, protein binding, and biomarker studies.

Frontage Virtual Tour: Do a 3D walkthrough of our site at 760 Pennsylvania Dr, Exton, PA 19341. In 2021 we opened our new 71,000-square-foot laboratory facility in Exton, PA. This new location supports our Bioanalytical, CMC, and Central Lab businesses. Our Bioanalytical suites focus on large molecules, biomarkers, and genomics. Our CMC laboratories feature a large analytical automation lab for small and large molecules, microbiology, and cell-based assays. Our large central laboratory includes a dedicated histology and pathology suite.